实用医学杂志 ›› 2021, Vol. 37 ›› Issue (23): 3077-3081.doi: 10.3969/j.issn.1006⁃5725.2021.23.023

• 综述 • 上一篇    下一篇

晚期糖基化终末产物受体途径在川崎病中的研究进展

周忠 王锋 田正 焦蓉   

  1. 湖北医药学院附属襄阳市第一人民医院(湖北襄阳441000)

  • 出版日期:2021-12-10 发布日期:2021-12-10
  • 通讯作者: 焦蓉 E⁃mail:jiaorong1125@163.com
  • 基金资助:
    湖北省卫生健康委科研项目(编号:WJ2021F064);襄阳市科学技术局项目(编号:2020ZD34);湖北医药学院研究生科技创新项目(编号:YC2021031)

Recent advances in relationship between advanced glycation end products receptor pathways and Kawasa⁃ ki disease

ZHOU Zhong,WANG Feng,TIAN Zheng,JIAO Rong.    

  1. Department of PediatricsXiangyang No.1 People′s HospitalHubei University of MedicineXiangyang 441000China
  • Online:2021-12-10 Published:2021-12-10
  • Contact: JIAO Rong E⁃mail:jiaorong1125@163.com

摘要:

晚期糖基化终末产物受体(receptor for advanced glycation end products,RAGE)属于一种细胞 表面免疫球蛋白超家族分子,表达于多种细胞表面,如单核巨噬细胞、血管内皮细胞、平滑肌细胞及神经 元细胞等。目前川崎病(Kawasaki disease,KD)的发病机制尚不明确,但近年来发现 RAGE 在川崎病循环 内皮细胞高表达。在体内多种配体可与 RAGE 结合,通过介导炎症因子释放和炎症通路活化等作用来影 KD 的发病。阻断 RAGE 的策略可能干预川崎病冠脉病变进程,以期待为川崎病提供新的治疗方法。 本文对RAGE 途径在川崎病中的研究进展及阻断RAGE 的策略进行综述。

关键词:

晚期糖基化终末产物受体,  , 川崎病,  , 冠状动脉病变

Abstract:

Receptor for advanced glycation end products(RAGE)belongs to a cell surface immunoglobulin superfamily molecule,which is expressed on a variety of cell surfaces,such as monocyte macrophages,vascular endothelial cells,smooth muscle cells and neuron cells. At present,the pathogenesis of Kawasaki disease(KD)is not clear,but in recent years,it has been found that expression of receptor for advanced glycation end products on the surface of circulating endothelial cells is upregulated in KD. In vivo,a variety of ligands can bind to RAGE which mediates the release of inflammatory factors and activation of inflammatory pathways,thus affecting the pathogenesis of KD. Blocking RAGE pathway may interfere with the progression of coronary artery lesions in Kawa⁃ saki disease,and it is expected to provide a new targeted treatment for KD. This article reviews the research prog⁃ ress of RAGE pathway in KD and the strategy of blocking RAGE.

Key words:

receptor for advanced glycation end products, Kawasaki disease, coronary arterial lesions